A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.
Epistemonikos ID: 7a88fa1ff6b795c924a3da4be713e804548e2f4e
First added on: Dec 20, 2022